Dillmann-Arroyo C, Cantú-Leal R, Campa-Núñez H, López-Cavazos C, Bermúdez-Argüelles M, Mejía-Herrera JC

Language: Spanish
References: 22
Page: 27-31
PDF size: 456.59 Kb.

ABSTRACT

Background: The non-invasive diagnosis of vertebral osteomyelitis is a difficult one. Studies confirm MRI as the gold standard with 92% sensitivity and 94% specificity. Scintigraphy combined with Tc99-Ga67 used to be the procedure of choice before the advent of PET with labeled glucose, which has a high sensitivity and specificity, but cannot distinguish a focus of infection from inflammation. Scintigraphy with UBI29-41 is an infection-specific study that was recently described in the literature. There are no studies showing its value in the diagnosis of vertebral osteomyelitis. Objective: The purpose of the study is to show that the Tc99-UBI29-41 scan has 99% sensitivity for vertebral osteomyelitis. Methods: This is a study of a diagnostic test. The case series was composed of the records of UBI scans performed at the Nuclear Medicine Department, HcHMAE. The scans were interpreted in a blind and independent fashion by 2 experienced observers. The final diagnosis was obtained with the histopathologic study or a microbiologic culture or with the clinical findings after a follow-up of at least 6 months. The sensitivity, specificity, positive and negative predictive values, and the positive and negative probability ratio were determined, always using a 95% confidence interval (CI). The sample size necessary to show 99% sensitivity with a 95% CI and a statistical power of 80% was 15 patients. The concordance with the kappa index was determined. Results: Twenty-seven patients with suspected vertebral osteomyelitis were included; 15 males and 12 females, with a mean age of 50 years (SD = 16). Fourteen patients had a history of surgery and 12 had metallic implants. Nine patients had a history if spinal infiltrations. The number of patients with a positive scan was 20. The sensitivity for detecting pyogenic vertebral osteomyelitis was 100% (CI: 0.901-1) and the specificity was 87.5% (CI: 0.647-0.875). The positive predictive value was 0.95 (CI: 0.859-0.950), and the negative predictive value was 1 (CI: 0.739-1). The intra- and interobserver kappa value was 1. Conclusions: The UBI scan showed 100% sensitivity and 88% specificity for vertebral osteomyelitis. Although the role of this method in the diagnostic protocol of the patient with suspected vertebral osteomyelitis has not yet been defined, the scan was useful in this group of patients to arrive at a certain diagnosis.

REFERENCES

1. Tay BK: Spinal Infections. JAAOS. 2002; 10(3): 188-97.

2. Seabold JE: Imaging techniques for evaluation of postoperative orthopaedic infections. Q J Nucl Med 1999; 43(1): 21-8.

3. Hain SF, Functional imaging and the orthopedic surgeon. JBJS Bri 2002; 84B: 315-21.

4. Boerman OC: Radiopharmaceuticals to image infection and inflammation. Semin Nuclear Medicine 2001; 31(4): 286-91.

5. De Winter F: 18-Fluorine fluorodeoxyglucose positron emission tomography for the diagnosis of infection in the postoperative spine. Spine 2003; 28(12): 1314-9.

6. Love C: Radionuclide imaging of infection. J Nucl Med Technol 2004; 32(2): 47-57.

7. Gratz S: 18F-FDG hybrid PET in patients with suspected spondylitis. Eur J Nucl Med Mol Imaging 2002; 29(4): 516-24.

8. Gemmel F: Radionuclide imaging of spinal infections. Eur J Nucl Med Molecular Imaging 2006; 33(10): 1226-37.

9. Imam SK: Radiotracers for imaging of infection and inflammation-A review. World J Nucl Med 2006; 5: 40-55.

10. Buscombe JR: The future of infection imaging. The Quartely Journal of Nuclear Medicine and Molecular Imaging 2006; 50(2): 104-12.

11. Akhtar MS: Antimicrobial Peptide 99mTc-Ubiquicidin 29-41 as human infection-imaging agent: clinical trial. J Nucl Med 2005; 46(4): 567-73.

12. Hiemstra PS: Ubiquicidin, a novel murine microbicidal protein in the cytosolic fraction of the activated macrophages. J Leukocyte Biol. PMID: 10496312. 1999.

13. Welling MM: Radiochemical and biological characteristics of 99mTc-UBI 29-41 for imaging of bacterial infections. Nucl Med Biol PMID: 12031876. 2002; 29(4): 413-22.

14. Epand RM: Diversity of antimicrobial peptides and their mechanisms of action. Biochim Biophys Acta 1999; 1462(1-2): 11-28.

15. Ferro-Flores G: In vitro and in vivo assessment of 99mTc-UBI specificity for bacteria. Nucl Med Biol PMID: 12900285. 2003; 30(6): 597-603.

16. Sergienko VB: Imaging if inflammatory foci with 99m technetium labeled antimicrobial oligopeptide. Vestn Roentgenol Radiol. PMID: 17633887. 2006.

17. Welling MM. Technetium 99m labeled antimicrobial peptides discriminate between bacterial infections and sterile inflammations. Eur J Nuc Med PMID: 19774881. 2000.

18. Welling MM: 99mTc labeled antimicrobial peptides for detection of bacterial and Candida albicans infections. J Nucl Med PMID: 11337578. 2001; 42(5): 788-94.

19. Akhtar MS: 99mTc labeled antimicrobial peptide ubiquicidina (29-41) accumulates less in Escherichia coli infection than in Staphylococcus aureus infection. J Nucl Med 2004. PMID: 15136636.

20. Lupetti A: 99mTc-antimicrobial peptides: promising candidates for infection imaging. Q J Nucl Med. PMID: 14973416. 2003; 47(4): 238-45.

21. Nibbering PH: 99mTc-labelled UBI 29-41 peptide for monitoring the efficacy of antibacterial agents in mice infected with Staphylococcus aureus. J Nucl Med PMID: 14960656. 2004; 45(2): 321-6.

22. Melendez-Alafort L: Biokinetics of 99mTc-UBI 29-41 in humans. Nucl Med Biol PMID: 15028250. 2004; 31(3): 373-9